Name: Verbetering van chimere antigeenreceptor-extracellulaire blaasjes (CAR-EV) -technologie: de toekomst van kankertherapie (Video) | JoVE Journal
Uploaded: 2025-09-19T13:20:00.000+00:00
Duration: 7 min 33 s
Description: Ontdek de ontwikkeling van CAR-EV-technologie voor gerichte kankertherapie met verbeterde isolatiemethoden. Deze innovatieve aanpak levert veilige, effectieve celvrije behandelingen voor solide tumoren.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

playerTrialDesktop

<ol><li>Park, J. H., Geyer, M. B., Brentjens, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CD19-targeted+CAR+T-cell+therapeutics+for+hematologic+malignancies%3A+Interpreting+clinical+outcomes+to+date%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date.</a> Blood. 127 (26), 3312-3320 (2016).</li>
<li>Jain, M. D., Smith, M., Shah, N. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((How+I+treat+refractory+CRS+and+ICANS+following+CAR+T-cell+therapy%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">How I treat refractory CRS and ICANS following CAR T-cell therapy.</a> Blood. 141 (20), 2430-2442 (2023).</li>
<li>Tang, X. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Therapeutic+potential+of+CAR-T+cell-derived+exosomes%3A+A+cell-free+modality+for+targeted+cancer+therapy%5BTitle%5D)+AND+%22Oncotarget%22%5BJournal%5D)">Therapeutic potential of CAR-T cell-derived exosomes: A cell-free modality for targeted cancer therapy.</a> Oncotarget. 6 (42), 44179-44190 (2015).</li>
<li>St-Denis-Bissonnette, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+clinically+relevant+large-scale+biomanufacturing+workflow+to+produce+natural+killer+cells+and+natural+killer+cell-derived+extracellular+vesicles+for+cancer+immunotherapy%5BTitle%5D)+AND+%22JEV%22%5BJournal%5D)">A clinically relevant large-scale biomanufacturing workflow to produce natural killer cells and natural killer cell-derived extracellular vesicles for cancer immunotherapy.</a> JEV. 12 (12), e12387(2023).</li>
<li>Jiang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hypoxia+enhances+the+production+and+antitumor+effect+of+exosomes+derived+from+natural+killer+cells%5BTitle%5D)+AND+%22Ann+Transl+Med%22%5BJournal%5D)">Hypoxia enhances the production and antitumor effect of exosomes derived from natural killer cells.</a> Ann Transl Med. 9 (6), 473-473 (2021).</li>
<li>Decot, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Natural-killer+cell+amplification+for+adoptive+leukemia+relapse+immunotherapy%3Acomparison+of+three+cytokines+IL-2%2C+IL-15%2C+or+IL-7+and+impact+on+NKG2D%2C+KIR2DL1%2C+and+KIR2DL2+expression%5BTitle%5D)+AND+%22Exp+Hematol%22%5BJournal%5D)">Natural-killer cell amplification for adoptive leukemia relapse immunotherapy:comparison of three cytokines IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.</a> Exp Hematol. 38 (5), 351-362 (2010).</li>
<li>Kim, I. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Functional+enhancement+of+exosomes+derived+from+NK+cells+by+IL-15+and+IL-21+synergy+against+hepatocellular+carcinoma+cells%3A+The+cytotoxicity+and+apoptosis+in+vitro+study%5BTitle%5D)+AND+%22Heliyon%22%5BJournal%5D)">Functional enhancement of exosomes derived from NK cells by IL-15 and IL-21 synergy against hepatocellular carcinoma cells: The cytotoxicity and apoptosis in vitro study.</a> Heliyon. 9 (6), e16962-e16962 (2023).</li>
<li>Mehdiani, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+innovative+method+for+exosome+quantification+and+size+measurement%5BTitle%5D)+AND+%22J+Vis+Exp%22%5BJournal%5D)">An innovative method for exosome quantification and size measurement.</a> J Vis Exp. (95), e50974(2015).</li>
<li>Bachurski, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extracellular+vesicle+measurements+with+nanoparticle+tracking+analysis-an+accuracy+and+repeatability+comparison+between+NanoSight+NS300+and+ZetaView%5BTitle%5D)+AND+%22JEV%22%5BJournal%5D)">Extracellular vesicle measurements with nanoparticle tracking analysis-an accuracy and repeatability comparison between NanoSight NS300 and ZetaView.</a> JEV. 8 (1), 1596016(2019).</li>
<li>Khanabdali, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+throughput+surface+epitope+immunoaffinity+isolation+of+extracellular+vesicles+and+downstream+analysis%5BTitle%5D)+AND+%22Biol+Methods+Protoc%22%5BJournal%5D)">High throughput surface epitope immunoaffinity isolation of extracellular vesicles and downstream analysis.</a> Biol Methods Protoc. 9 (1), bpae032(2024).</li>
<li>Salomon, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Early+detection+of+ovarian+cancer%3A+An+accurate+high-throughput+extracellular+vesicle+test%5BTitle%5D)+AND+%22J+Clin+Oncol%22%5BJournal%5D)">Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test.</a> J Clin Oncol. 43 (16_suppl), 5582-5582 (2025).</li>
<li>Fu, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CAR+exosomes+derived+from+effector+CAR-T+cells+have+potent+antitumour+effects+and+low+toxicity%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.</a> Nat Commun. 10 (1), 1-12 (2019).</li>
<li>Zheng, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inhalable+CAR-T+cell-derived+exosomes+as+paclitaxel+carriers+for+treating+lung+cancer%5BTitle%5D)+AND+%22J+Transl+Med%22%5BJournal%5D)">Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer.</a> J Transl Med. 21 (1), 383(2023).</li>
<li>Tian, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineered+exosome+for+drug+delivery%3A+Recent+development+and+clinical+applications%5BTitle%5D)+AND+%22Int+J+Nanomed%22%5BJournal%5D)">Engineered exosome for drug delivery: Recent development and clinical applications.</a> Int J Nanomed. 18, 7923-7940 (2023).</li>
<li>Chen, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Encapsulation+and+assessment+of+therapeutic+cargo+in+engineered+exosomes%3Aa+systematic+review%5BTitle%5D)+AND+%22J+Nanobiotechnology%22%5BJournal%5D)">Encapsulation and assessment of therapeutic cargo in engineered exosomes:a systematic review.</a> J Nanobiotechnology. 22 (1), 18(2024).</li>
<li>Basyoni, A. E., Atta, A., Salem, M. M., Mohamed, T. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Harnessing+exosomes+for+targeted+drug+delivery+systems+to+combat+brain+cancer%5BTitle%5D)+AND+%22Cancer+Cell+Int%22%5BJournal%5D)">Harnessing exosomes for targeted drug delivery systems to combat brain cancer.</a> Cancer Cell Int. 25 (1), 150(2025).</li>
<li>Coughlan, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Exosome+isolation+by+ultracentrifugation+and+precipitation+and+techniques+for+downstream+analyses%5BTitle%5D)+AND+%22Curr+Protoc+Cell+Biol%22%5BJournal%5D)">Exosome isolation by ultracentrifugation and precipitation and techniques for downstream analyses.</a> Curr Protoc Cell Biol. 88 (1), e110(2020).</li>
<li>Zhang, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Large-scale+separation+and+purification+of+exosomes+using+ion-exchange+chromatography%5BTitle%5D)+AND+%22Biomed+Res+Ther%22%5BJournal%5D)">Large-scale separation and purification of exosomes using ion-exchange chromatography.</a> Biomed Res Ther. 11 (4), 6348-6356 (2024).</li>
<li>Fernandes, R. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeted+isolation+of+extracellular+vesicles+from+cell+culture+supernatant+using+immuno-affinity+chromatography%5BTitle%5D)+AND+%22Sep+Purif+Technol%22%5BJournal%5D)">Targeted isolation of extracellular vesicles from cell culture supernatant using immuno-affinity chromatography.</a> Sep Purif Technol. 358 (Part A), 130312-130312 (2024).</li>
<li>Jiang, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-EGFR+ScFv+functionalized+exosomes+delivering+LPCAT1+specific+siRNAs+for+inhibition+of+lung+cancer+brain+metastases%5BTitle%5D)+AND+%22JNB%22%5BJournal%5D)">Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases.</a> JNB. 22 (1), 159(2024).</li>
<li>Dobersberger, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+engineering+strategy+to+target+activated+EGFR+with+CAR+T+cells%5BTitle%5D)+AND+%22Cell+Rep+Methods%22%5BJournal%5D)">An engineering strategy to target activated EGFR with CAR T cells.</a> Cell Rep Methods. 4 (4), 100728-100728 (2024).</li>
<li>Shi, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bispecific+CAR+T+cell+therapy+targeting+BCMA+and+CD19+in+relapsed%2Frefractory+multiple+myeloma%3Aa+phase+I%2FII+trial%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma:a phase I/II trial.</a> Nat Commun. 15 (1), 3371(2024).</li>
<li>Roddie, G., Amrolia, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dual+targeting+CAR-T+cells+for+B-cell+acute+lymphoblastic+leukaemia+and+B-cell+non-Hodgkin+lymphoma%5BTitle%5D)+AND+%22Blood+Adv%22%5BJournal%5D)">Dual targeting CAR-T cells for B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma.</a> Blood Adv. 9 (4), 704-721 (2024).</li>
</ol>

<table><tbody><tr><td>Materials</td><td></td><td></td><td></td></tr><tr><td>1x phosphate buffered saline (PBS), pH 7.4</td><td>Gibco</td><td>10010049</td><td>EV verrijking</td></tr><tr><td>1% sodium dodecyl sulfate (SDS)</td><td>Sigma</td><td>L3771-100G</td><td>Los 1g SDS poeder op in 10 mL ultrapuur water</td></tr><tr><td>1x tris buffered saline met Tween-20 (TBST)</td><td>Thermo Scientific Chemicals</td><td>J77500.K2</td><td>Verdun met ultrapuur water tot een 1x oplossing (alternatief, bereid een 0,1% polysorbaat-20/Tween-20 oplossing in 1x tris buffered saline)</td></tr><tr><td>96-wells heldere platte bodem polystyreen TC-behandelde microplaat, steriele</td><td>Corning</td><td>3595</td><td>In vitro functioneel assay</td></tr><tr><td>Bolt Bis-Tris Plus Mini Protein Gels, 4-12%, 1,0 mm, WedgeWell formaat</td><td>Invitrogen</td><td></td><td>Cel/EV karakterisering</td></tr><tr><td>Bovien serum albumine</td><td>Sigma-Aldrich</td><td>A9647-100G</td><td>Cel/EV karakterisering</td></tr><tr><td>Calnexin antilichaam</td><td>Cell Signaling</td><td>2433S</td><td>Cel/EV karakterisering</td></tr><tr><td>CAR-NK/T cellen</td><td>ProMab Biotechnologies</td><td>Varieert</td><td>CAR extracellulaire ligand-bindende domein hangt af van de voorkeursdoelwit op recipient cellen</td></tr><tr><td>CellTiter 96 AQueous One Solution Cel Proliferatie Assay (MTS)</td><td>Promega</td><td>G3580</td><td>In vitro functioneel assay</td></tr><tr><td>cOmplete, Mini, EDTA-vrije Protease Inhibitor Cocktail</td><td>Roche</td><td>11836170001</td><td>Cel lysis</td></tr><tr><td>ECL Western blotting detectiereagens</td><td>Amersham</td><td>RPN2232</td><td>Cel/EV karakterisering</td></tr><tr><td>Elutie buffer</td><td>INOVIQ</td><td></td><td>EV verrijking/isolatie</td></tr><tr><td>Equilibratie buffer</td><td>INOVIQ</td><td></td><td>EV verrijking/isolatie</td></tr><tr><td>EXO-ACE IEX kolom</td><td>INOVIQ</td><td></td><td>EV verrijking/isolatie voor downstream functionele assay Patent-ID AU2024901931</td></tr><tr><td>EXO-NET pan-exosome opvangkralen</td><td>INOVIQ</td><td></td><td>EV isolatie voor downstream karakterisering Patent-ID WO/2014/011673</td></tr><tr><td>Granzyme B antilichaam</td><td>Cell Signaling</td><td>4275</td><td>Cel/EV karakterisering</td></tr><tr><td>Human IL-2 IS, premium grade</td><td>Miltenyi Biotec</td><td>130-097-744</td><td>Xeno-vrije cultuur van T/NK cellen</td></tr><tr><td>iBlot 2 Transfer Stacks, PVDF</td><td>Invitrogen</td><td></td><td>Cel/EV karakterisering</td></tr><tr><td>ImmunoCult-XF (cGMP)</td><td>Stemcell Technologies</td><td>100-0956</td><td>Xeno-vrije cultuur van T/NK cellen</td></tr><tr><td>K-562</td><td>ATCC</td><td>CCL-243</td><td>In vitro functioneel assay</td></tr><tr><td>MCF-7</td><td>ATCC</td><td>HTB-22</td><td>In vitro functioneel assay</td></tr><tr><td>Millex-GP spuitfilterunit, 0,22 &micro;m</td><td>Merck Millipore</td><td>SLGPR33RS</td><td>Terminale filtratie</td></tr><tr><td>Regeneratie buffer</td><td>INOVIQ</td><td></td><td>EV verrijking/isolatie</td></tr><tr><td>RIPA buffer (10X)</td><td>Cell Signaling Technology</td><td>9806</td><td>Cel lysis</td></tr><tr><td>Trypan blauw oplossing, 0,4%</td><td>Gibco</td><td>15250061</td><td>Beoordeling van cellevensvatbaarheid en dichtheid</td></tr><tr><td>Wash buffer</td><td>INOVIQ</td><td></td><td>EV verrijking/isolatie</td></tr><tr><td>Equipment</td><td></td><td></td><td></td></tr><tr><td>Automatische celteller</td><td>Invitrogen</td><td>Countess II FL</td><td>Beoordeling van cellevensvatbaarheid en dichtheid</td></tr><tr><td>Benchtop geautomatiseerd extractie-instrument</td><td>Invitrogen</td><td>KingFisher Apex System</td><td>Hoge doorvoer geautomatiseerd zuiveringssysteem Zie link voor protocol details: https://www.inoviq.com/site/technology/resources</td></tr><tr><td>Fluorescentiemicroscoop</td><td>Zeiss</td><td>Axio Observer 7</td><td>Cel cultuur</td></tr><tr><td>Nanoparticle tracking analyse (NTA)</td><td>Particle Metrix GmbH</td><td>Zetaview PMX-130</td><td>Deeltjesanalyse</td></tr><tr><td>Plate reader</td><td>BMG Labtech</td><td>SPECTROstar Nano</td><td>In vitro functioneel assay</td></tr><tr><td>Gekoelde benchtop centrifuge</td><td>Beckman Coulter</td><td>Avanti J-15R</td><td>Cel cultuur & EV verrijking verwerking</td></tr><tr><td>SDS-PAGE mini gel tank</td><td>Invitrogen</td><td>A25977</td><td>Cel/EV karakterisering</td></tr><tr><td>Western blot transfer systeem</td><td>Invitrogen</td><td>iBlot 2</td><td>Cel/EV karakterisering</td></tr></tbody></table>

verbetering van chimere antigeenreceptor-extracellulaire blaasjes (car-ev) -technologie: de toekomst van kankertherapie

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Verbetering van chimere antigeenreceptor-extracellulaire blaasjes (CAR-EV) -technologie: de toekomst van kankertherapie

CAR cell therapies have significantly advanced personalized treatment for several hematological malignancies. Currently, seven CAR-&#8239;cell products ...

enhancing-chimeric-antigen-receptor-extracellular-vesicles-car-ev

Research

JoVE Journal

Biology

Biologie

This video demonstrates a technique to manufacture chimeric antigen receptor (CAR) T cells ex vivo. Human T cells are incubated with magnetic beads coated with anti-CD3 and anti-CD28 antibodies, along with a medium supplemented with interleukin-2 (IL-2), leading to T cell activation and proliferation. Transgenic lentiviral vectors are introduced, allowing the transgenic RNA to integrate into the host genome and express the transgene. This results in the transduced T cells expressing chimeric...

An Ex Vivo Technique to Manufacture Chimeric Antigen Receptor T Cells

This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...

An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells

De lymfodeletieve en immunomodulerende effecten van chemotherapie en stralingsstandaardzorg kunnen worden benut om de antitumor-effectiviteit van T-celimmunotherapie te verbeteren. We schetsen een methode voor het genereren van EGFRvIII-specifieke chimere antigeenreceptor (CAR) T-cellen en het toedienen ervan in de context van glioblastoma standaardzorg.

Generatie van de CAR T-cellen voor adoptieve Therapie in de context van glioblastoma Standard of Care

We beschrijven een kwantitatieve real-time in vitro cytolysis assay systeem om de potentie van chimere antigeen receptor T-cellen gericht op vloeibare en solide tumorcellen te evalueren. Dit protocol kan worden uitgebreid om andere immuuneffector cellen te beoordelen, evenals combinatie behandelingen.

Een real-time potentie test voor Chimerische antigeen receptor T-cellen gericht op vaste en hematologische kankercellen

Hier beschrijven we een in vitro co cultuur methode recursief uitdaging tumor-gerichte T-cellen, die het mogelijk voor fenotypische en functionele analyse van antitumorale T cel activiteit maakt.

In Vitro Tumor cel Rechallenge voor voorspellende evaluatie van chimeer antigeen Receptor T cel antitumorale functie

We beschrijven een aanpak om betrouwbaar te genereren chimeer antigeen receptor (auto) T cellen en testen hun differentiatie en functie in vitro en in vivo.

Productie van Chimerische antigeen receptor (auto) T cellen voor adoptie immunotherapie

Dit protocol stroomlijnt de productie van retrovirale vectoren en de transductie van T-cellen bij muizen, waardoor de efficiënte generatie van CAR-T-cellen van muizen wordt vergemakkelijkt.

Efficiënte generatie van muizen chimere antigeenreceptor (CAR)-T-cellen

Dit protocol schetst een gedetailleerde procedure voor het genereren van voorbijgaande chimere antigeenreceptor (CAR) T-cellen met behulp van niet-integrerend mRNA voor kankerimmunotherapie en biedt betrouwbare methoden voor het evalueren van CAR-T-cellen en hun cytotoxische functie.

Een niet-virale benadering om voorbijgaande chimere antigeenreceptor-T-cellen te genereren met behulp van mRNA voor immunotherapie bij kanker

Dit protocol beschrijft de essentiële stappen voor de kweek van primaire T-cellen, waaronder hun isolatie, activatie, expansie en tijdelijke transfectie door mRNA-elektroporatie. Daarnaast worden een workflow en antilichaampanel voorgesteld voor flowcytometrische analyse van fenotype, activatiemarkers, levensvatbaarheid en chimere antigeenreceptor (CAR)-expressie.

Isolatie, cultivatie en tijdelijke transfectie van primaire menselijke T-cellen om chimerische antigeenreceptoren (CAR) T-cellen te genereren

De komst van site-specific recombinase (SSR) technologie en het Cre / lox systeem heeft geleid tot tal van ontwikkelingen in de moleculaire biologie, en heeft zichzelf bewezen als een waardevol instrument voor de beoordeling van gen-functie in transgene dieren. Dit interview bespreekt het mechanisme van de site van de specifieke recombinatie door cyclisatie recombinase (Cre) en hoe het gebruik van dit enzym heeft geleid tot de ontwikkeling van voorwaardelijke mutagenese, hetgeen aanzienlijke...

Principes van site-specifieke recombinase (SSR) Technologie

Ontdek de ontwikkeling van CAR-EV-technologie voor gerichte kankertherapie met verbeterde isolatiemethoden. Deze innovatieve aanpak levert veilige, effectieve celvrije behandelingen voor solide tumoren.

Verbetering van chimere antigeenreceptor-extracellulaire blaasjes (CAR-EV) -technologie: de toekomst van kankertherapie

Meer video's verkennen